Latest Breaking News On - Sixth element capital - Page 1 : comparemela.com

NeoPhore raises an additional £9 6m (USD $12 2m) Series B financing extension to further progress drug discovery pipeline

NeoPhore raises an additional £9 6m (USD $12 2m) Series B financing extension to further progress drug discovery pipeline
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomCity ofSimon fiduciariaIntesa sanpaoloMatthew bakerStefano buonoRobert jamesElement capitalHead of communications investorB future health fundPioneer fundIntesa sanpaolo innovation centerAstellas pharma incPhoremost ltdUniversity to industry

NeoPhore s small molecule drugs pipeline gets additional £9 6M

A company building a pipeline of small molecule drugs targeting novel proteins across the DNA mismatch repair (pathway) has announced a further extension to its series B financing round.

United statesIntesa sanpaoloStefano buonoMatthew bakerSimon fiduciariaRobert jamesB future health fundErsel groupNeophore limitedSixth element capitalClaris venturesAstellas venture managementBfuture health fundMarkets amp regulationsDrug deliveryClinical development

NeoPhore Raises Additional £9 6M in Series B Extension Financing

FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!

City ofUnited kingdomIntesa sanpaoloSimon fiduciariaMatthew bakerStefano buonoUniversity of turinPhoremost ltdPioneer fundB future health fundUnited kingdom basedSixth element capitalClaris venturesAstellas venture managementBfuture health fund

Leucid Bio Raises £11 5M in Series A Funding

FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!

United kingdomCity ofIan miscampbellGraziano seghezziMartin diggleMichael garrisonJohn maherHeikki lanckrietLeucid bioKing college londonNational institute for health researchFund of the british business bankSt thoma biomedical research centreVulpes life science fundPartner of sixth element capitalLondon united kingdom based

Leucid Bio Raises £11 5M in Series A Financing to Develop Next Generation of Innovative Chimeric Antigen Receptor T cell (CAR-T) Therapies

/PRNewswire/ Leucid Bio ("Leucid" or the "Company"), a biotech company pioneering next-generation cell therapies for hard-to-treat cancers, today announces.

France generalUnited kingdomCity ofIan miscampbellGraziano seghezziMartin diggleMichael garrisonJohn maherPrnewswire leucid bioLeucid bioKing college londonVulpes investment management pte ltdResearch excellence frameworkSt thoma biomedical research centreVulpes life science fundDr john maher at king college london